Share Twitter LinkedIn Facebook Email Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas explains the promising role of CAR-T cell therapies in lymphoma patients.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read